SPOP Mutations in Prostate Cancer across Demographically Diverse Patient Cohorts

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: WFRF:(Fall Katja) > SPOP Mutations in P...

LIBRIS Formathandbok (Information om MARC21)

Fältnamn	Indikatorer	Metadata
000		07216naa a2200637 4500
001		oai:DiVA.org:oru-35221
003		SwePub
008		140602s2014 \| \|\|\|\|\|\|\|\|\|\|\|000 \|\|eng\|
024	7	a https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-352212 URI
024	7	a https://doi.org/10.1593/neo.1317042 DOI
040		a (SwePub)oru
041		a engb eng
042		9 SwePub
072	7	a ref2 swepub-contenttype
072	7	a art2 swepub-publicationtype
100	1	a Blattner, Mirjamu Dept Pathol & Lab Med, Inst Precis Med, Weill Med Coll, Cornell Univ, New York, USA4 aut
245	1 0	a SPOP Mutations in Prostate Cancer across Demographically Diverse Patient Cohorts
264	1	a New York :b Elsevier,c 2014
338		a print2 rdacarrier
500		a Funding Agencies:National Cancer Institute 1RO1CA125612 5UO1CA11275Prostate Cancer FoundationSystemsX.ch grant (PhosphoNet-PPM)Prostate Cancer Foundation Young Investigator AwardUrology Care Foundation Research Scholar Award
520		a BACKGROUND: Recurrent mutations in the Speckle-Type POZ Protein (SPOP) gene occur in up to 15% of prostate cancers. However, the frequency and features of cancers with these mutations across different populations is unknown.OBJECTIVE: To investigate SPOP mutations across diverse cohorts and validate a series of assays employing high-resolution melting (HRM) analysis and Sanger sequencing for mutational analysis of formalin-fixed paraffin-embedded material.DESIGN, SETTING, AND PARTICIPANTS: 720 prostate cancer samples from six international cohorts spanning Caucasian, African American, and Asian patients, including both prostate-specific antigen-screened and unscreened populations, were screened for their SPOP mutation status. Status of SPOP was correlated to molecular features (ERG rearrangement, PTEN deletion, and CHD1 deletion) as well as clinical and pathologic features.RESULTS AND LIMITATIONS: Overall frequency of SPOP mutations was 8.1% (4.6% to 14.4%), SPOP mutation was inversely associated with ERG rearrangement (P < .01), and SPOP mutant (SPOPmut) cancers had higher rates of CHD1 deletions (P < .01). There were no significant differences in biochemical recurrence in SPOPmut cancers. Limitations of this study include missing mutational data due to sample quality and lack of power to identify a difference in clinical outcomes.CONCLUSION: SPOP is mutated in 4.6% to 14.4% of patients with prostate cancer across different ethnic and demographic backgrounds. There was no significant association between SPOP mutations with ethnicity, clinical, or pathologic parameters. Mutual exclusivity of SPOP mutation with ERG rearrangement as well as a high association with CHD1 deletion reinforces SPOP mutation as defining a distinct molecular subclass of prostate cancer.
650	7	a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650	7	a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653		a RADICAL RETROPUBIC PROSTATECTOMY; MELTING ANALYSIS; SURVIVAL RATES; EFFICIENT; TMPRSS2; FUSION
653		a Onkologi
653		a Oncology
700	1	a Lee, Daniel J.u Dept Pathol & Lab Med, Inst Precis Med, Weill Med Coll, Cornell Univ, New York, USA; Dept Urol, Weill Med Coll, Cornell Univ, New York, USA4 aut
700	1	a O'Reilly, Catherineu Dept Pathol & Lab Med, Inst Precis Med, Weill Med Coll, Cornell Univ, New York NY, USA4 aut
700	1	a Park, Kyungu Dept Pathol & Lab Med, Inst Precis Med, Weill Med Coll, Cornell Univ, New York NY, USA4 aut
700	1	a MacDonald, Theresa Y.u Dept Pathol & Lab Med, Inst Precis Med, Weill Med Coll, Cornell Univ, New York NY, USA4 aut
700	1	a Khani, Francescau Dept Pathol & Lab Med, Inst Precis Med, Weill Med Coll, Cornell Univ, New York NY, USA4 aut
700	1	a Turner, Kevin R.u Dept Pathol & Lab Med, Inst Precis Med, Weill Med Coll, Cornell Univ, New York NY, USA4 aut
700	1	a Chiu, Ya-Linu Dept Biostat & Epidemiol, Weill Med Coll, Cornell Univ, New York NY, USA4 aut
700	1	a Wild, Peter J.u Inst Surg Pathol, Univ Zurich Hosp, Zurich, Switzerland4 aut
700	1	a Dolgalev, Igoru Human Oncol & Pathogenesis Program, Mem Sloan Kettering Canc Ctr, New York NY, USA4 aut
700	1	a Heguy, Adrianau Human Oncol & Pathogenesis Program, Mem Sloan Kettering Canc Ctr, New York NY, USA4 aut
700	1	a Sboner, Andreau Dept Pathol & Lab Med, Inst Precis Med, New York NY, USA; Weill Med Coll, Cornell Univ, Inst Computat Biomed, New York, NY, USA; Inst Precis Med, Weill Med Coll, Cornell Univ, New York NY, USA4 aut
700	1	a Ramazangolu, Sinanu Dept Pathol & Lab Med, Inst Precis Med, Weill Med Coll, Cornell Univ, New York NY, USA; Inst Computat Biomed, Weill Med Coll, Cornell Univ, New York NY, USA4 aut
700	1	a Hieronymus, Haleyu Inst Computat Biomed, Weill Med Coll, Cornell Univ, New York NY, USA4 aut
700	1	a Sawyers, Charlesu Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York NY, USA4 aut
700	1	a Tewari, Ashutosh K.u Dept Urol, Weill Med Coll, Cornell Univ, New York NY, USA4 aut
700	1	a Moch, Holgeru Inst Surg Pathol, Univ Zurich Hosp, Zurich, Switzerland4 aut
700	1	a Yoon, Ghil Suku Sch Med, Dept Pathol, Kyungpook Natl Univ, Taegu, South Korea4 aut
700	1	a Known, Yong Chulu Sch Med, Dept Pathol, Catholic Univ Daegu, Taegu, South Korea4 aut
700	1	a Andrén, Ove,d 1963-u Örebro universitet,Institutionen för hälsovetenskap och medicin,Region Örebro län,Dept Urol, Örebro University Hospital, Örebro, Sweden4 aut0 (Swepub:oru)oan
700	1	a Fall, Katja,d 1971-u Örebro universitet,Institutionen för hälsovetenskap och medicin4 aut0 (Swepub:oru)kafl
700	1	a Demichelis, Francecsau Inst Precis Med, Weill Med Coll, Cornell Univ, New York NY, USA; Ctr Integrat Biol, Univ Trento, Trento, Italy4 aut
700	1	a Mosquera, Juan Miguelu Dept Pathol & Lab Med, Inst Precis Med, Weill Med Coll, Cornell Univ, New York NY, USA4 aut
700	1	a Robinson, Brian D.u Dept Pathol & Lab Med, Inst Precis Med, Weill Med Coll, Cornell Univ, New York NY, USA; Dept Urol, Weill Med Coll, Cornell Univ, New York NY, USA4 aut
700	1	a Barbieri, Christopher E.u Dept Pathol & Lab Med, Inst Precis Med, Weill Med Coll, Cornell Univ, New York NY, USA; Dept Urol, Weill Med Coll, Cornell Univ, New York NY, USA4 aut
700	1	a Rubin, Mark A.u Dept Pathol & Lab Med, Inst Precis Med, Weill Med Coll, Cornell Univ, New York NY, USA; Dept Urol, Weill Med Coll, Cornell Univ, New York NY, USA; Inst Precis Med, Weill Med Coll, Cornell Univ, New York NY, USA4 aut
710	2	a Dept Pathol & Lab Med, Inst Precis Med, Weill Med Coll, Cornell Univ, New York, USAb Dept Pathol & Lab Med, Inst Precis Med, Weill Med Coll, Cornell Univ, New York, USA; Dept Urol, Weill Med Coll, Cornell Univ, New York, USA4 org
773	0	t Neoplasiad New York : Elsevierg 16:1, s. 14-U34q 16:1<14-U34x 1522-8002x 1476-5586
856	4	u https://doi.org/10.1593/neo.131704
856	4 8	u https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-35221
856	4 8	u https://doi.org/10.1593/neo.131704

Hitta via bibliotek

Neoplasia (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Cancer och onkol ...

Artiklar i publikationen: Neoplasia

Av lärosätet: Örebro universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se